Moreover, the expression of immune checkpoints, such as PD-L1, PD-1, and CTLA-4, and their relationship to the clinical phenotype in GIST are emerging as potential prognostic biomarkers and could lead to improved prognostication in GIST, traditionally based on mitotic indices, tumor location, and tumor size [5,11,12,13]. The gene discussed is CD274; the disease is gastrointestinal stromal tumor.